Results 61 to 70 of about 407,045 (310)

Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt   +5 more
wiley   +1 more source

Determination of an unrelated donor pool size for human leukocyte antigen-matched platelets in Brazil

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2016
Background: Successful transfusion of platelet refractory patients is a challenge. Many potential donors are needed to sustain human leukocyte antigen matched-platelet transfusion programs because of the different types of antigens and the constant needs
Carolina Bonet Bub   +4 more
doaj   +1 more source

Association between human leukocyte antigen and COVID-19 severity

open access: yesActa Medica Iranica, 2021
In the last days of 2019, a new coronavirus emerged in Wuhan, China, and less than 3 months its disease now called COVID-19 was announced a global pandemic by WHO.
Reza Hajebi   +7 more
doaj   +1 more source

Rheumatologic Manifestations of Patients With Type B Insulin Resistance

open access: yesArthritis Care &Research, EarlyView.
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya   +4 more
wiley   +1 more source

Inhibitor of Apoptosis Proteins as Novel Targets in Inflammatory Processes [PDF]

open access: yes, 2013
Objective: Inhibitor of apoptosis proteins (IAPs), such as X-linked or cellular IAP 1/2 (XIAP, cIAP1/2), are important regulators of apoptosis. IAP antagonists are currently under clinical investigation as anticancer agents.
Erhardt, Annette   +10 more
core   +1 more source

Infusible Extracellular Matrix Biomaterial Enhances Cell‐Specific Pro‐Repair Responses Following Acute Myocardial Infarction

open access: yesAdvanced Healthcare Materials, EarlyView.
We measure the cell‐specific responses of administering infusible ECM (iECM) in acute myocardial infarction (MI) across multiple timepoints. Using single‐nucleus RNA sequencing and spatial transcriptomics, we measure macrophage activation, fibroblast remodeling, increased vascular development, lymphangiogenesis, cardioprotection, and neurogenesis ...
Joshua M. Mesfin   +18 more
wiley   +1 more source

HLA Class I and Class II Polymorphisms and Anti-nuclear Antibodies in Hyperprolactinaemic Iraqi Females with Primary Infertility

open access: yesمجلة كلية الطب, 2009
Background: The study was conducted to investigate the association between hyperprolactinaemia and markers of human leukocyte antigen (HLA) system in a sample of Iraqi infertile females, together with the profile anti-nuclear antibodies (ANA ...
Ali H. Ad'hiah   +3 more
doaj   +1 more source

A role for Syk-kinase in the control of the binding cycle of the β2 integrins (CD11/CD18) in human polymorphonuclear neutrophils [PDF]

open access: yes, 2003
A fine control of β2 integrin (CD11/CD18)-mediated firm adhesion of human neutrophils to the endothelial cell monolayer is required to allow ordered emigration.
Arnaout   +47 more
core   +1 more source

Macrophage Membrane‐Cloaked, ROS‐Triggered Quercetin Nanocarriers Target Ovarian Lesions to Treat Polycystic Ovary Syndrome

open access: yesAdvanced Healthcare Materials, EarlyView.
The synthesis process of MM@PCD@QNPs and its potential mechanism for treating PCOS. (A) Assembly steps of MM@PCD@QNPs. (B) Synthesis and decomposition of MM@PCD@QNPs. (C) Potential therapeutic mechanisms of MM@PCD@QNPs for PCOS. PCD, PABP conjugated with DEX polymer; QUR, quercetin; CDI, N, N′‐carbonyldiimidazole; DEX, dextran; PABP, 4‐(hydroxymethyl ...
Wenzhu Li   +9 more
wiley   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

open access: yesAdvanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy